Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Bath & Body Works does a majority of its manufacturing in the United States, so tariff policies won’t significantly affect ...

Fintel reports that on April 17, 2025, BMO Capital downgraded their outlook for Novo Nordisk A (NYSE:NVO) from Outperform to ...

NEW YORK, April 9 (Reuters) - BMO Capital on Wednesday cut its year-end 2025 S&P 500 (.SPX), opens new tab target by 9% to 6,100 from the prior 6,700, citing the speed and severity of the recent ...

Tuesday afternoon's $69 billion sale of 2-year Treasury notes was met with below-average bidding by nondealers. The auction produced a tail of a half basis point amid soft demand and nondealer bidding ...

Fintel reports that on April 7, 2025, BMO Capital upgraded their outlook for Saia (NasdaqGS:SAIA) from Market Perform to Outperform. Analyst Price Forecast Suggests 57.74% Upside As of April 2, 2025, ...

BMO Capital lowered the firm’s price target on CSX (CSX) to $35 from $36 but keeps an Outperform rating on the shares. The company’s Q1 ...

U.S. government debt was mostly rallying as of Tuesday morning, led by interest in 20- and 30-year bonds, amid a dearth of major data releases and as traders remain attuned to any further attacks by ...

CSX (NASDAQ:CSX – Free Report) had its price target trimmed by BMO Capital Markets from $36.00 to $35.00 in a research note published on Thursday,Benzinga reports.The firm currently has an ...

Investing.com -- BMO Capital Markets upgraded Check Point Software Technologies (NASDAQ:CHKP) Ltd to Outperform from Market Perform, citing increased confidence in the company’s growth ...